blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3412680

EP3412680 - NOVEL PEPTIDES THAT BIND TO TYPES OF MHC CLASS II AND THEIR USE IN DIAGNOSIS AND TREATMENT [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.09.2021
Database last updated on 16.07.2024
FormerThe patent has been granted
Status updated on  02.10.2020
FormerGrant of patent is intended
Status updated on  04.06.2020
FormerExamination is in progress
Status updated on  21.10.2019
FormerRequest for examination was made
Status updated on  28.06.2019
FormerThe application has been published
Status updated on  09.11.2018
Most recent event   Tooltip03.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 05.06.2024  [2024/23]
Applicant(s)For all designated states
Curara AB
Sälgstigen 4
181 62 Lidingö / SE
[2018/50]
Inventor(s)01 / Klareskog, Lars
Vanadisvägen 22B
113 46 Stockholm / SE
02 / Malmström, Vivianne
Vintertullstorget 16
116 43 Stockholm / SE
 [2018/50]
Representative(s)Kransell & Wennborg KB
P.O. Box 27834
115 93 Stockholm / SE
[2018/50]
Application number, filing date18151231.005.04.2012
[2018/50]
Priority number, dateSE2011005029705.04.2011         Original published format: SE 1150297
US201161472122P05.04.2011         Original published format: US 201161472122 P
[2018/50]
Previously filed application, dateWO2012SE5037805.04.2012
[2018/50]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3412680
Date:12.12.2018
Language:EN
[2018/50]
Type: A3 Search report 
No.:EP3412680
Date:19.12.2018
Language:EN
[2018/51]
Type: B1 Patent specification 
No.:EP3412680
Date:04.11.2020
Language:EN
[2020/45]
Search report(s)(Supplementary) European search report - dispatched on:EP21.11.2018
ClassificationIPC:C07K7/08, A61K38/10, A61P29/00, A61P37/02, C07K14/78, C07K14/47, G01N33/564
[2018/51]
CPC:
C07K14/78 (EP,US); A61K38/014 (US); A61K39/0008 (US);
A61K39/001 (US); A61P29/00 (EP); A61P37/02 (EP);
C07K14/47 (EP,US); C07K14/70539 (EP,US); C07K19/00 (EP,US);
C12N9/88 (EP,US); C12Y402/01011 (EP,US); G01N33/564 (EP,US);
G01N33/56977 (EP,US); A61K2035/122 (US); A61K38/00 (EP,US);
G01N2333/525 (US); G01N2333/54 (US); G01N2333/57 (US);
G01N2333/7051 (US); G01N2333/70514 (US); G01N2333/70539 (US);
G01N2333/70575 (US); G01N2333/988 (US); G01N2800/102 (EP,US);
G01N2800/24 (US) (-)
Former IPC [2018/50]C07K7/08, A61K38/10, A61P29/00, A61P37/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/31]
Former [2018/50]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:NEUARTIGE PEPTIDE ZUR BINDUNG AN EINZELNE TYPEN DER MHC-KLASSE-II UND DEREN VERWENDUNG IN DIAGNOSE UND BEHANDLUNG[2018/50]
English:NOVEL PEPTIDES THAT BIND TO TYPES OF MHC CLASS II AND THEIR USE IN DIAGNOSIS AND TREATMENT[2018/50]
French:NOUVEAUX PEPTIDES QUI SE LIENT À DES TYPES DE MHC DE CLASSE II ET LEUR UTILISATION DANS LE DIAGNOSTIC ET LE TRAITEMENT[2018/50]
Examination procedure19.06.2019Amendment by applicant (claims and/or description)
19.06.2019Examination requested  [2019/31]
19.06.2019Date on which the examining division has become responsible
24.10.2019Despatch of a communication from the examining division (Time limit: M04)
11.02.2020Reply to a communication from the examining division
05.06.2020Communication of intention to grant the patent
23.09.2020Fee for grant paid
23.09.2020Fee for publishing/printing paid
23.09.2020Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP12768393.6  / EP2694530
Opposition(s)05.08.2021No opposition filed within time limit [2021/41]
Fees paidRenewal fee
11.01.2018Renewal fee patent year 03
11.01.2018Renewal fee patent year 04
11.01.2018Renewal fee patent year 05
11.01.2018Renewal fee patent year 06
15.03.2018Renewal fee patent year 07
29.04.2019Renewal fee patent year 08
11.02.2020Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.04.2012
AL04.11.2020
AT04.11.2020
CY04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
IT04.11.2020
LT04.11.2020
LV04.11.2020
MC04.11.2020
MK04.11.2020
NL04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SI04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
LU05.04.2021
BE30.04.2021
[2024/23]
Former [2023/33]HU05.04.2012
AL04.11.2020
AT04.11.2020
CY04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
IT04.11.2020
LT04.11.2020
LV04.11.2020
MC04.11.2020
NL04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SI04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
LU05.04.2021
BE30.04.2021
Former [2023/24]AL04.11.2020
AT04.11.2020
CY04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
IT04.11.2020
LT04.11.2020
LV04.11.2020
MC04.11.2020
NL04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SI04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
LU05.04.2021
BE30.04.2021
Former [2022/34]AL04.11.2020
AT04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
IT04.11.2020
LT04.11.2020
LV04.11.2020
MC04.11.2020
NL04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SI04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
LU05.04.2021
BE30.04.2021
Former [2022/23]AL04.11.2020
AT04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
IT04.11.2020
LT04.11.2020
LV04.11.2020
MC04.11.2020
NL04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SI04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
LU05.04.2021
Former [2022/10]AL04.11.2020
AT04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
IT04.11.2020
LT04.11.2020
LV04.11.2020
MC04.11.2020
NL04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SI04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
PT04.03.2021
LU05.04.2021
Former [2022/04]AL04.11.2020
AT04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
IT04.11.2020
LT04.11.2020
LV04.11.2020
MC04.11.2020
NL04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SI04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
LU05.04.2021
Former [2021/50]AL04.11.2020
AT04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
IT04.11.2020
LT04.11.2020
LV04.11.2020
MC04.11.2020
NL04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SI04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/48]AL04.11.2020
AT04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
IT04.11.2020
LT04.11.2020
LV04.11.2020
NL04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/46]AL04.11.2020
AT04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
LT04.11.2020
LV04.11.2020
NL04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/45]AL04.11.2020
AT04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
LT04.11.2020
LV04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/37]AT04.11.2020
CZ04.11.2020
DK04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
LT04.11.2020
LV04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/36]AT04.11.2020
CZ04.11.2020
EE04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
LT04.11.2020
LV04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/35]AT04.11.2020
CZ04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
LT04.11.2020
LV04.11.2020
PL04.11.2020
RO04.11.2020
RS04.11.2020
SK04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/33]AT04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
LT04.11.2020
LV04.11.2020
PL04.11.2020
RS04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/32]AT04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
LV04.11.2020
PL04.11.2020
RS04.11.2020
SM04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/28]AT04.11.2020
ES04.11.2020
FI04.11.2020
HR04.11.2020
LV04.11.2020
PL04.11.2020
RS04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/25]AT04.11.2020
ES04.11.2020
FI04.11.2020
LV04.11.2020
PL04.11.2020
RS04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
IS04.03.2021
PT04.03.2021
Former [2021/24]AT04.11.2020
FI04.11.2020
LV04.11.2020
RS04.11.2020
BG04.02.2021
NO04.02.2021
GR05.02.2021
PT04.03.2021
Former [2021/23]FI04.11.2020
LV04.11.2020
RS04.11.2020
NO04.02.2021
GR05.02.2021
PT04.03.2021
Former [2021/22]FI04.11.2020
RS04.11.2020
NO04.02.2021
PT04.03.2021
Former [2021/21]FI04.11.2020
PT04.03.2021
Former [2021/20]FI04.11.2020
Documents cited:Search[X]WO2004078098  (LONDON HEALTH SCI CT RES INC [CA], et al) [X] 1,3,4,6,7,9,10 * claims 1, 18, 35; sequence 32 *;
 [XI]WO2006128492  (ENTELECHON GMBH [DE], et al) [X] 1,2 * page 11; table 1 * [I] 10;
 [XDI]WO2007123976  (UNIV LELAND STANFORD JUNIOR [US], et al) [XD] 1,3,4 * antigen vim58-77cit; page 14 * * paragraph [0035] * [I] 10;
 [X]WO2007133702  (CELL SIGNALING TECHNOLOGY INC [US], et al) [X] 1,2 * line 303 (SEQ ID NO: 302); page 28 *;
 [XI]WO2008090360  (IMP INNOVATIONS LTD [GB], et al) [X] 1,2 * page 7, lines 1-27 * * Peptide 11; page 45; table 2 * [I] 4-8,10,11;
 [XI]WO2008099419  (COUNCIL SCIENT IND RES [IN], et al) [X] 1,2 * spot 59b, 59c; page 23; table 3 * [I] 10;
 [XI]WO2009055820  (UNIV CALIFORNIA [US], et al) [X] 1,2 * figure 9d * [I] 10;
 [A]  - C CHARPIN ET AL, "HLA-DRB1*0404 is strongly associated with high titers of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, (20080101), vol. 26, no. 4, pages 627 - 631, XP055149681 [A] 1,2,4-8,10,11 * the whole document *
 [A]  - WEGNER N ET AL, "Evolutionarily conserved antigens in autoimmune disease: Implications for an infective aetiology", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, PERGAMON, GB, vol. 41, no. 2, doi:10.1016/J.BIOCEL.2008.09.012, ISSN 1357-2725, (20090201), pages 390 - 397, (20080924), XP026006727 [A] 1,2,4-8,10,11 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.biocel.2008.09.012
by applicantWO03050542
 WO2007017556
 WO2007123976
 WO2008090360
 US2009221792
 US2009292108
    - R. B. MERRIFIELD, J. Am. Chem. Soc., (19630000), vol. 85, no. 14, pages 2149 - 2154
    - MERRIFIELD, Int. J. Peptide. Protein Res, (19900000), vol. 35, pages 161 - 214
    - ATHERTON E. et al., Bioorg Chem., (19790000), vol. 8, page 351
    - JOE SAMBROOK, Molecular Cloning: A Laboratory Manual
    - NOVAK EJ; LIU AW; NEPOM GT, "Kwok WW MHC class II tetramers identify peptide-specific human CD4+ T cells proliferating in response to influenza A antigen", J Clin Invest, (19990000), vol. 104, pages R63 - 7
    - DZHAMBAZOV, B. et al., "Therapeutic Vaccination of Active Arthritis with a Glycosylated Collagen Type II Peptide in Complex with MHC Class II Molecules", J Immunol, (20060000), vol. 176, pages 1525 - 1533, XP003008498
    - SMITH, K.J.; PYRDOL, J.; GAUTHIER, L.; WILEY, D.C.; WUCHERPFENNIG, K.W., "Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein", J Exp Med, (19980000), vol. 188, doi:doi:10.1084/jem.188.8.1511, pages 1511 - 1520, XP002228793

DOI:   http://dx.doi.org/10.1084/jem.188.8.1511
    - ANDERSSON, E.C. et al., "Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice", Proc Natl Acad Sci U S A, (19980000), vol. 95, pages 7574 - 7579
    - SVENDSEN, P. et al., "Tracking of proinflammatory collagen-specific T cells in early and late collagen-induced arthritis in humanized mice", J Immunol, (20040000), vol. 173, pages 7037 - 7045, XP002661381
    - LARCHE; WRAITH, "Peptide-based therapeutic vaccines for allergic and autoimmune disease", Nature Medicine Supplement, (20050000), vol. 11, no. 4, doi:doi:10.1038/NM1226, pages S69 - S76, XP002509273

DOI:   http://dx.doi.org/10.1038/NM1226
    - LUDVIGSSON et al., GAD N Engl J Med., (20081030), vol. 359, no. 18, pages 1909 - 20
    - TISCH et al., J Immunol., (20090000), vol. 183, pages 4809 - 4816
    - VESTBERG et al., J Immunol., (20060000), vol. 176, pages 1525 - 1533
    - SHAH et al., Journal of Internal Medicine, (20090000), vol. 266, pages 221 - 23
    - GIANFRANI et al., J Immunol., (20090000), vol. 182, pages 4158 - 4166
    - OLERUP O; ZETTERQUIST H, "HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation", Tissue Antigens, (19920000), vol. 39, pages 225 - 35, XP009090040
    - SNIR et al., Arthritis & Rheumatism, vol. 63, no. 10, pages 2873 - 2883
    - NOVAK et al., J Clin Invest, (19990000), vol. 104, pages R63 - 7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.